Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04603495




Registration number
NCT04603495
Ethics application status
Date submitted
20/10/2020
Date registered
26/10/2020
Date last updated
28/10/2024

Titles & IDs
Public title
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
Scientific title
A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients
Secondary ID [1] 0 0
2020-001989-10
Secondary ID [2] 0 0
CPI 0610-04
Universal Trial Number (UTN)
Trial acronym
MANIFEST-2
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Myelofibrosis 0 0
Primary Myelofibrosis 0 0
Post-polycythemia Vera Myelofibrosis 0 0
Post-essential Thrombocythemia Myelofibrosis 0 0
Condition category
Condition code
Blood 0 0 0 0
Haematological diseases
Blood 0 0 0 0
Other blood disorders
Musculoskeletal 0 0 0 0
Other muscular and skeletal disorders
Human Genetics and Inherited Disorders 0 0 0 0
Other human genetics and inherited disorders
Cancer 0 0 0 0
Leukaemia - Chronic leukaemia

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Pelabresib
Treatment: Drugs - Ruxolitinib
Treatment: Drugs - Placebo

Experimental: Pelabresib + ruxolitinib - Pelabresib monohydrate tablets + ruxolitinib phosphate tablets

Active comparator: Placebo + ruxolitinib - Matching placebo tablets + ruxolitinib phosphate tablets


Treatment: Drugs: Pelabresib
Double-blind treatment (pelabresib or matching placebo) will be administered daily for 14 consecutive days followed by a 7-day break, which is considered 1 cycle of treatment (1 cycle = 21 days).

Pelabresib is a small molecule inhibitor of BET proteins with a novel mechanism of action and potential for disease-modifying effects in MF.

Treatment: Drugs: Ruxolitinib
Ruxolitinib is a JAK inhibitor and a current, approved treatment option for MF.

Treatment: Drugs: Placebo
Placebo tablets are designed to match pelabresib tablets. Each placebo tablet contains no active pharmaceutical ingredient and is visibly identical to experimental drug in size, shape, and packaging. Placebo dosing follows the same dosing conventions as pelabresib.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Participants With Splenic Response by Central Reads at Week 24
Timepoint [1] 0 0
24 weeks of treatment
Secondary outcome [1] 0 0
Total Symptom Score Absolute Change From Baseline to Week 24
Timepoint [1] 0 0
24 weeks of treatment
Secondary outcome [2] 0 0
Number of Participants With TSS50 Response at Week 24
Timepoint [2] 0 0
24 weeks of treatment

Eligibility
Key inclusion criteria
* Aged = 18 years
* Confirmed diagnosis of myelofibrosis (primary, post-polycythemia vera, or post essential thrombocythemia)
* Adequate hematologic, renal, and hepatic function
* Have at least 2 symptoms with an average score = 3 or an average total score of = 10 over the 7-day period prior to randomization using the MFSAF v4.0
* Prognostic risk-factor score of Intermediate-1 or higher per Dynamic International Prognostic Scoring System (DIPSS) scoring system
* Spleen volume of = 450 cm^3
* Eastern Cooperative Oncology Group (ECOG) performance status = 2
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Splenectomy or splenic irradiation in the previous 6 months
* Chronic or active conditions and/or concomitant medication use that would prohibit treatment
* Had prior treatment with any JAKi or BET inhibitor for treatment of a myeloproliferative neoplasm

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
9/04/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/12/2027
Actual
Sample size
Target
Accrual to date
Final
430
Recruitment in Australia
Recruitment state(s)
QLD,SA,VIC
Recruitment hospital [1] 0 0
Icon Cancer Centre - Brisbane
Recruitment hospital [2] 0 0
Royal Adelaide Hospital - Adelaide
Recruitment hospital [3] 0 0
Monash Health - Clayton
Recruitment hospital [4] 0 0
Peninsula Private Hospital Clinical Trials Unit - Frankston
Recruitment hospital [5] 0 0
USC Clinical Trials Centre Sunshine Coast Haematology and Oncology Clinic - Buderim
Recruitment hospital [6] 0 0
One Clinical Research PTY LTD - Nedlands
Recruitment postcode(s) [1] 0 0
4101 - Brisbane
Recruitment postcode(s) [2] 0 0
5000 - Adelaide
Recruitment postcode(s) [3] 0 0
3168 - Clayton
Recruitment postcode(s) [4] 0 0
3199 - Frankston
Recruitment postcode(s) [5] 0 0
QLD 4556 - Buderim
Recruitment postcode(s) [6] 0 0
6009 - Nedlands
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Indiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Kentucky
Country [9] 0 0
United States of America
State/province [9] 0 0
Michigan
Country [10] 0 0
United States of America
State/province [10] 0 0
Missouri
Country [11] 0 0
United States of America
State/province [11] 0 0
New York
Country [12] 0 0
United States of America
State/province [12] 0 0
Ohio
Country [13] 0 0
United States of America
State/province [13] 0 0
Texas
Country [14] 0 0
United States of America
State/province [14] 0 0
Washington
Country [15] 0 0
Austria
State/province [15] 0 0
Graz
Country [16] 0 0
Austria
State/province [16] 0 0
Linz
Country [17] 0 0
Austria
State/province [17] 0 0
Salzburg
Country [18] 0 0
Belgium
State/province [18] 0 0
Antwerpen
Country [19] 0 0
Belgium
State/province [19] 0 0
Brussel
Country [20] 0 0
Belgium
State/province [20] 0 0
La Louvière
Country [21] 0 0
Belgium
State/province [21] 0 0
Leuven
Country [22] 0 0
Belgium
State/province [22] 0 0
Liège
Country [23] 0 0
Canada
State/province [23] 0 0
Alberta
Country [24] 0 0
Canada
State/province [24] 0 0
Ontario
Country [25] 0 0
Canada
State/province [25] 0 0
Quebec
Country [26] 0 0
Czechia
State/province [26] 0 0
Hradec Kralove
Country [27] 0 0
Czechia
State/province [27] 0 0
Olomouc
Country [28] 0 0
France
State/province [28] 0 0
Amiens
Country [29] 0 0
France
State/province [29] 0 0
Le Mans
Country [30] 0 0
France
State/province [30] 0 0
Nice
Country [31] 0 0
France
State/province [31] 0 0
Nîmes
Country [32] 0 0
France
State/province [32] 0 0
Pierre-Bénite
Country [33] 0 0
France
State/province [33] 0 0
Rennes
Country [34] 0 0
France
State/province [34] 0 0
Saint-Priest-en-Jarez
Country [35] 0 0
France
State/province [35] 0 0
Tours
Country [36] 0 0
France
State/province [36] 0 0
Vandœuvre-lès-Nancy
Country [37] 0 0
Germany
State/province [37] 0 0
Baden-Württemberg
Country [38] 0 0
Germany
State/province [38] 0 0
Bayern
Country [39] 0 0
Germany
State/province [39] 0 0
Sachsen
Country [40] 0 0
Germany
State/province [40] 0 0
Thüringen
Country [41] 0 0
Germany
State/province [41] 0 0
Hamburg
Country [42] 0 0
Greece
State/province [42] 0 0
Athens
Country [43] 0 0
Greece
State/province [43] 0 0
Ioánnina
Country [44] 0 0
Greece
State/province [44] 0 0
Río
Country [45] 0 0
Hong Kong
State/province [45] 0 0
Kowloon
Country [46] 0 0
Hong Kong
State/province [46] 0 0
New Territories
Country [47] 0 0
Hungary
State/province [47] 0 0
Pecs
Country [48] 0 0
Hungary
State/province [48] 0 0
Nyíregyháza
Country [49] 0 0
Israel
State/province [49] 0 0
Be'er Sheva
Country [50] 0 0
Israel
State/province [50] 0 0
Be'er Ya'aqov
Country [51] 0 0
Israel
State/province [51] 0 0
Haifa
Country [52] 0 0
Israel
State/province [52] 0 0
H_olon
Country [53] 0 0
Israel
State/province [53] 0 0
Jerusalem
Country [54] 0 0
Israel
State/province [54] 0 0
Nahariya
Country [55] 0 0
Israel
State/province [55] 0 0
Petah Tikva
Country [56] 0 0
Israel
State/province [56] 0 0
Tel Aviv
Country [57] 0 0
Italy
State/province [57] 0 0
Bergamo
Country [58] 0 0
Italy
State/province [58] 0 0
Bologna
Country [59] 0 0
Italy
State/province [59] 0 0
Brescia
Country [60] 0 0
Italy
State/province [60] 0 0
Ferrara
Country [61] 0 0
Italy
State/province [61] 0 0
Florence
Country [62] 0 0
Italy
State/province [62] 0 0
Meldola
Country [63] 0 0
Italy
State/province [63] 0 0
Milano
Country [64] 0 0
Italy
State/province [64] 0 0
Monza
Country [65] 0 0
Italy
State/province [65] 0 0
Novara
Country [66] 0 0
Italy
State/province [66] 0 0
Orbassano
Country [67] 0 0
Italy
State/province [67] 0 0
Padova
Country [68] 0 0
Italy
State/province [68] 0 0
Palermo
Country [69] 0 0
Italy
State/province [69] 0 0
Rome
Country [70] 0 0
Italy
State/province [70] 0 0
Turin
Country [71] 0 0
Italy
State/province [71] 0 0
Varese
Country [72] 0 0
Korea, Republic of
State/province [72] 0 0
Gyeongsangnam-do
Country [73] 0 0
Korea, Republic of
State/province [73] 0 0
Busan
Country [74] 0 0
Korea, Republic of
State/province [74] 0 0
Daegu
Country [75] 0 0
Korea, Republic of
State/province [75] 0 0
Gyeonggi-do
Country [76] 0 0
Korea, Republic of
State/province [76] 0 0
Incheon
Country [77] 0 0
Korea, Republic of
State/province [77] 0 0
Jeonju
Country [78] 0 0
Korea, Republic of
State/province [78] 0 0
Seoul
Country [79] 0 0
Korea, Republic of
State/province [79] 0 0
Ulsan
Country [80] 0 0
Malaysia
State/province [80] 0 0
Johor
Country [81] 0 0
Malaysia
State/province [81] 0 0
Kedah
Country [82] 0 0
Malaysia
State/province [82] 0 0
Penang
Country [83] 0 0
Malaysia
State/province [83] 0 0
Selangor
Country [84] 0 0
Malaysia
State/province [84] 0 0
Kota Kinabalu
Country [85] 0 0
Netherlands
State/province [85] 0 0
Amsterdam
Country [86] 0 0
Netherlands
State/province [86] 0 0
Maastricht
Country [87] 0 0
Poland
State/province [87] 0 0
Biala Podlaska
Country [88] 0 0
Poland
State/province [88] 0 0
Gdansk
Country [89] 0 0
Poland
State/province [89] 0 0
Katowice
Country [90] 0 0
Poland
State/province [90] 0 0
Skorzewo
Country [91] 0 0
Poland
State/province [91] 0 0
Torun
Country [92] 0 0
Spain
State/province [92] 0 0
Asturias
Country [93] 0 0
Spain
State/province [93] 0 0
Badalona
Country [94] 0 0
Spain
State/province [94] 0 0
Barcelona
Country [95] 0 0
Spain
State/province [95] 0 0
Caceres
Country [96] 0 0
Spain
State/province [96] 0 0
Las Palmas de Gran Canaria
Country [97] 0 0
Spain
State/province [97] 0 0
Madrid
Country [98] 0 0
Spain
State/province [98] 0 0
Murcia
Country [99] 0 0
Spain
State/province [99] 0 0
Salamanca
Country [100] 0 0
Spain
State/province [100] 0 0
Sevilla
Country [101] 0 0
Spain
State/province [101] 0 0
Toledo
Country [102] 0 0
Spain
State/province [102] 0 0
Valencia
Country [103] 0 0
Taiwan
State/province [103] 0 0
Chiayi City
Country [104] 0 0
Taiwan
State/province [104] 0 0
Taichung
Country [105] 0 0
Taiwan
State/province [105] 0 0
Taipei
Country [106] 0 0
Thailand
State/province [106] 0 0
Hat Yai District
Country [107] 0 0
Thailand
State/province [107] 0 0
Lak Si
Country [108] 0 0
Thailand
State/province [108] 0 0
Mueang Khon Kaen District
Country [109] 0 0
Thailand
State/province [109] 0 0
Pathumwan
Country [110] 0 0
Thailand
State/province [110] 0 0
Ratchathewi District
Country [111] 0 0
Turkey
State/province [111] 0 0
Ankara
Country [112] 0 0
Turkey
State/province [112] 0 0
Antalya
Country [113] 0 0
Turkey
State/province [113] 0 0
Edirne
Country [114] 0 0
Turkey
State/province [114] 0 0
Gaziantep
Country [115] 0 0
Turkey
State/province [115] 0 0
Izmir
Country [116] 0 0
Turkey
State/province [116] 0 0
Kayseri
Country [117] 0 0
Turkey
State/province [117] 0 0
Kocaeli
Country [118] 0 0
Turkey
State/province [118] 0 0
Mersin
Country [119] 0 0
Turkey
State/province [119] 0 0
Samsun
Country [120] 0 0
United Kingdom
State/province [120] 0 0
Scotland
Country [121] 0 0
United Kingdom
State/province [121] 0 0
Wales
Country [122] 0 0
United Kingdom
State/province [122] 0 0
Boston
Country [123] 0 0
United Kingdom
State/province [123] 0 0
Cambridge
Country [124] 0 0
United Kingdom
State/province [124] 0 0
Liverpool
Country [125] 0 0
United Kingdom
State/province [125] 0 0
London
Country [126] 0 0
United Kingdom
State/province [126] 0 0
Oxford

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Constellation Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
A Phase 3, randomized, blinded study comparing pelabresib (CPI-0610) and ruxolitinib with placebo and ruxolitinib in myelofibrosis (MF) patients that have not been previously treated with Janus kinase inhibitors (JAKi). Pelabresib is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.
Trial website
https://clinicaltrials.gov/study/NCT04603495
Trial related presentations / publications
Mascarenhas J, Kremyanskaya M, Patriarca A, Harrison C, Bose P, Rampal RK, Palandri F, Devos T, Passamonti F, Hobbs G, Talpaz M, Vannucchi A, Kiladjian JJ, Verstovsek S, Hoffman R, Salama ME, Chen D, Taverna P, Chang A, Colak G, Klein S, Gupta V. MPN-375 BET Inhibitor Pelabresib (CPI-0610) Combined With Ruxolitinib in Patients With Myelofibrosis - JAK Inhibitor-Naie or With Suboptimal Response to Ruxolitinib - Preliminary Data From the MANIFEST Study. Clin Lymphoma Myeloma Leuk. 2022 Oct;22 Suppl 2:S335-S336. doi: 10.1016/S2152-2650(22)01456-2.
Harrison CN, Gupta VK, Gerds AT, Rampal R, Verstovsek S, Talpaz M, Kiladjian JJ, Mesa R, Kuykendall AT, Vannucchi AM, Palandri F, Grosicki S, Devos T, Jourdan E, Wondergem MJ, Al-Ali HK, Buxhofer-Ausch V, Alvarez-Larran A, Patriarca A, Kremyanskaya M, Mead AJ, Akhani S, Sheikine Y, Colak G, Mascarenhas J. Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis. Future Oncol. 2022 Sep;18(27):2987-2997. doi: 10.2217/fon-2022-0484. Epub 2022 Aug 11.
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT04603495